Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Oncology | Obstetrics/Gynecology
Disease Category: Cervical Cancer
Trial Information
A Randomized Phase III Study of Paclitaxel + Cisplatin versus Vinorelbine + Cisplatin versus Gemcitabine + Cisplatin versus Topotecan + Cisplatin in Stage IVB, Recurrent or Persistent Carcinoma of the Cervix [GOG0204]
This is research study for women who have a malignant cervical
tumor which cannot be cured by surgery or radiation therapy. The
purpose of this research study is to determine the best
chemotherapy drug to be given with cisplatin. Chemotherapy with
cisplatin and paclitaxel is the standard treatment for cancer of
the cervix in this situation. The study drugs used in this study
are vinorelbine, gemcitabine and topotecan. Study participants have
an equal chance of being placed in any one of the following 4
groups:
1) cisplatin + paclitaxel
2) cisplatin + vinorelbine
3) cisplatin + gemcitabine
4) cisplatin + topotecan
No Compensation Provided
Patient Inclusion/Exclusion Criteria:
You may be eligible to participate if you
-are 18 years of age or older
-have been diagnosed with a malignant cervical tumor which cannot
be cured by surgery or radiation therapy
-meet additional criteria
You are not eligible for this study if you
-are pregnant or breastfeeding
-currently have another type of cancer other than skin cancer
-have been previously treated with chemotherapy except when used in
addition to radiation therapy
Rudy Segna, MD, Prinicpal Investigator
Mount Sinai Medical Center
One Gustave L. Levy Place
New York, NY 10029
Phone: 212-888-8439
Fax: 212-319-1140
EMail: rudy.segna@mssm.edu
View Google Map
If you would like to learn more about participating in this study, please send an e-mail message using the form below.
DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the
clinical trials industry. The information provided in this service is designed
to help patients find clinical trials that may be of interest to them, and to
help patients contact the centers conducting the research. CenterWatch is
neither promoting this research nor involved in conducting any of these
trials.
